The Beta Blocker Evaluation of Survival Trial (BEST) is an NHLBI and VA-sponsored multicenter investigation assessing whether an investigational beta blocker, bucindolol, impacts on survival in patients with Class III-IV congestive heart failure and ejection fraction of 35% or less. The study goal is 2,800 patients. The study remains in its recruitment phase and approximately 2,100 patients have been recruited to date.
Showing the most recent 10 out of 570 publications